An observational study in Hemorrhoidal Disease and Internal Hemorrhoids, sponsored by Sanliurfa Education and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Sanliurfa Education and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Patient Satisfaction with a site in Turkey — 32 open to participants now, 33 under way, none of them phase 3. Patient Satisfaction · Turkey.
Among the 131 studies in Patient Satisfaction with a site in Turkey, this one is the 22nd largest by planned enrollment of the 29 observational ones that give a count, is one of 29 that started in 2026, is one of 29 observational ones, reaches primary completion later than 19 of the 32 other live ones, and was the 107th registered.
882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.
Browse Patient Satisfaction studies →32 of the 131 studies in Patient Satisfaction with a site in Turkey are open now. Recruiting first, the newest first:
Ankara City Hospital Bilkent · Sites in Turkey
Ages 60+ · Healthy volunteers
Dokuz Eylul University · Sites in Turkey
Ages 18+
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–45 · Women only
Tarsus University · Sites in Turkey
Ages 18+ · Men only · Healthy volunteers
University of Yalova · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 150 across 227 observational studies indexed under Patient Satisfaction.
Median enrollment 90 across the 102 interventional studies, 120 across the 29 observational. Of the 93 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 131 have an industry lead sponsor. The 10 most frequent:
Sanliurfa Education and Research Hospital is the lead sponsor of 25 studies on the registry; 10 are open to participants now.
Sanliurfa Education and Research Hospital has 1 study filed under Patient Satisfaction — fewer than ten, so there is no comparison to draw.
17 of the studies in Patient Satisfaction with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07612982Marmara UniversityHybrid vs Fluoroscopy-Guided Interlaminar Epidural Injection in Lumbar Spinal Stenosis | 2026-11 |
| NCT07942714Ankara City Hospital BilkentBirth Satisfaction in Women After Spontaneous Vaginal Birth, Planned Cesarean, or Cesarean During Labor | 2026-12-10 |
| NCT07124494Konya City HospitalRegional Anesthesia in TKA: Impact on Postoperative Joint Motion and Patient Satisfaction | 2026-12-12 |
| NCT07520734Sanliurfa Education and Research HospitalClinical Outcomes After Laser Hemorrhoidoplasty | 2027-01-01 |
| NCT07586605University of YalovaLying Positions in Intramuscular Injection | 2027-01-30 |
Add all 17 to your calendar (.ics) → With an account.
Among the 131 studies in Patient Satisfaction with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center prospective observational study aims to evaluate clinical outcomes, postoperative pain scores, complications, and patient satisfaction in adults undergoing laser hemorrhoidoplasty for symptomatic internal hemorrhoidal disease. Additional objectives are to assess the relationship between hemorrhoid stage, dominant presenting symptoms, operative technical details, and postoperative outcomes. No study-specific intervention beyond routine clinical care and follow-up will be performed.
Hemorrhoidal disease is a common benign anorectal condition that can significantly impair quality of life. Conventional excisional techniques may be associated with postoperative pain, bleeding, prolonged recovery, and lower patient satisfaction. Laser hemorrhoidoplasty is a minimally invasive technique based on coagulation and shrinkage of hemorrhoidal tissue without excision. This prospective observational study will be conducted at the General Surgery Clinic of Sanliurfa Education and Research Hospital. Adult patients with symptomatic internal hemorrhoidal disease who are scheduled to undergo laser hemorrhoidoplasty will be enrolled. Preoperative symptoms, hemorrhoid stage, and physical examination findings will be recorded. Intraoperative data will include laser wavelength, total delivered energy, number of hemorrhoidal packages treated, and any additional surgical procedures. Postoperative pain will be assessed at predefined time points using the Visual Analog Scale. Analgesic requirement and duration, length of hospital stay, time to return to daily activities, early complications within 30 days, late complications, symptom status, and recurrence at 6 months will be documented. The study is designed to clarify the clinical role of laser hemorrhoidoplasty and help define appropriate patient selection criteria.
Adult patients with symptomatic internal hemorrhoidal disease who are scheduled to undergo laser hemorrhoidoplasty at the General Surgery Clinic of Sanliurfa Education and Research Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with symptomatic internal hemorrhoidal disease undergoing laser hemorrhoidoplasty.
Procedure: Laser Hemorrhoidoplasty
Laser-based minimally invasive treatment of internal hemorrhoidal disease performed as part of routine clinical care.
Postoperative pain score
Postoperative pain assessed using a 0 to 10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst imaginable pain; higher scores indicate worse pain.
Time frame: At 6 hours, 24 hours, and 1 week after surgery
Duration of postoperative analgesic use
Duration of postoperative analgesic use, measured in days.
Time frame: From the day of surgery through 30 days after surgery
Length of hospital stay
Postoperative hospital stay, measured in days from the date of surgery to the date of discharge.
Time frame: From the day of surgery to hospital discharge, up to 7 days
Incidence of predefined early postoperative complications
Number and proportion of patients who develop any predefined early postoperative complication within 30 days after laser hemorrhoidoplasty. Predefined complications include postoperative bleeding, urinary retention, anal thrombosis, infection, severe pain, and anal stenosis. Patients without any of these events will be classified as having no complication.
Time frame: Within 30 days after surgery
Time to return to daily activities
Time required to return to usual daily activities, measured in days.
Time frame: Up to 30 days after surgery
Patient satisfaction
Patient-reported satisfaction after laser hemorrhoidoplasty.
Time frame: Up to 3 months after surgery
Plan to share: No — Individual participant data will not be shared because this is a single-center study involving sensitive patient-level clinical data, and there is no pre-specified institutional mechanism for external data sharing. Only aggregated, de-identified study results will be reported.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.
Of 107 non-industry observational studies under Patient Satisfaction, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 45. This study's planned 7 months is below that.
Counting every sponsor, half of 113 studies reached it within 20 months; a quarter within 7 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanliurfa Education and Research Hospital